Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to follow the study procedures and attend all required follow-up visits.
• People who are able to provide written consent, or whose legal guardian is able to provide it on their behalf.
• People between 45 and 85 years of age.
• Women who are either past menopause (no periods for at least 12 months before the scan), have had a surgical procedure that prevents pregnancy (such as removal of ovaries or uterus), or who have been using a highly effective form of birth control (such as the pill for at least 3 months, an IUD for at least 2 months, or a barrier method like a diaphragm combined with spermicide) for at least 14 days before the study injection.
• Women of childbearing potential who are not pregnant, not breastfeeding, and not planning to become pregnant during the study, and who return a negative pregnancy test before certain study procedures.
• Healthy participants who are already enrolled in the PPMI study as a healthy subject.
• People with Parkinson's disease who are already enrolled in the PPMI study as a sporadic or LRRK2 Parkinson's disease participant, and who have known results from certain spinal fluid and blood tests (confirm with trial site).
• People with a diagnosis of Progressive Supranuclear Palsy (PSP) based on recognised medical criteria, whose symptoms began 2 to 5 years before screening, who have progressive movement symptoms including difficulty moving the eyes vertically and balance problems, and who have had an abnormal DaTscan brain scan showing changes in a part of the brain called the striatum.
• People with a diagnosis of Corticobasal Syndrome (CBS) based on recognised medical criteria, who have movement and thinking difficulties that are worse on one side of the body, specific movement problems such as difficulty using a limb purposefully or involuntary limb movements, thinking or memory difficulties, and an abnormal DaTscan showing changes in the striatum.

Who may not be able to join:

• People with another medical or psychiatric condition, or abnormal test results, that the study doctor considers would make participation unsuitable.
• People who are scheduled to receive a DaTscan as part of screening and who are currently taking certain medications that could interfere with the scan (such as methylphenidate, amphetamines, bupropion, or others listed in the criteria), and who are either unwilling or medically unable to stop taking them for the required period beforehand (confirm with trial site for the full medication list).
• People who have taken certain medications that affect dopamine in the brain — including some antipsychotic medications, metoclopramide, or reserpine — within 6 months before the relevant study visit.
• People whose brain MRI shows significant abnormalities or findings that suggest a neurological condition other than the one being studied, in the opinion of the study doctor.
• People who, for any other reason the study doctor considers relevant — including abnormal laboratory results — may not be safe to receive the study imaging agent, or who are otherwise considered unsuitable for the study.

Important: Always verify eligibility with the trial site directly before applying.